Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SLDB Solid Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: SLDB
Price (delayed)
$2.77
Market cap
$214.66M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.06
Enterprise value
$158.6M
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by
Highlights
The EPS rose by 37% year-on-year
The debt fell by 8% YoY and by 2.2% QoQ
The equity has declined by 18% since the previous quarter but it is up by 9% year-on-year
SLDB's quick ratio is down by 42% year-on-year and by 34% since the previous quarter
The net income fell by 30% YoY and by 22% QoQ
Key stats
What are the main financial stats of SLDB
Market
Valuations
Earnings
Shares outstanding
77.49M
Market cap
$214.66M
Enterprise value
$158.6M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.81
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$129.73M
Net income
-$124.7M
EBIT
-$124.36M
EBITDA
-$119.51M
Free cash flow
-$100.66M
Per share
Balance sheet
Liquidity
EPS
-$3.06
EPS diluted
-$3.06
Free cash flow per share
-$2.47
Book value per share
$3.44
Revenue per share
$0
TBVPS
$4.62
Total assets
$188.66M
Total liabilities
$51.42M
Debt
$24.18M
Equity
$137.25M
Working capital
$127.05M
Debt to equity
0.18
Current ratio
5.2
Quick ratio
4.92
Net debt/EBITDA
0.47
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-56.7%
Return on equity
-70.4%
Return on invested capital
-92.4%
Return on capital employed
-78.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SLDB stock price
How has the Solid Biosciences stock price performed over time
Intraday
6.95%
1 week
0.36%
1 month
9.92%
1 year
-70.22%
YTD
-30.75%
QTD
-25.14%
Financial performance
How have Solid Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$129.73M
Net income
-$124.7M
Gross margin
N/A
Net margin
N/A
The net income fell by 30% YoY and by 22% QoQ
The operating income has declined by 24% year-on-year and by 16% since the previous quarter
Price vs fundamentals
How does SLDB's price correlate with its fundamentals
Growth
What is Solid Biosciences's growth rate over time
Valuation
What is Solid Biosciences stock price valuation
P/E
N/A
P/B
0.81
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 37% year-on-year
The price to book (P/B) is 49% less than the last 4 quarters average of 1.6 and 42% less than the 5-year quarterly average of 1.4
The equity has declined by 18% since the previous quarter but it is up by 9% year-on-year
Efficiency
How efficient is Solid Biosciences business performance
The ROIC is down by 22% QoQ and by 7% YoY
Solid Biosciences's return on equity has decreased by 20% QoQ and by 13% YoY
The return on assets has declined by 19% since the previous quarter and by 16% year-on-year
Dividends
What is SLDB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SLDB.
Financial health
How did Solid Biosciences financials performed over time
Solid Biosciences's current ratio has decreased by 42% YoY and by 34% QoQ
SLDB's quick ratio is down by 42% year-on-year and by 34% since the previous quarter
The debt is 82% lower than the equity
The debt to equity has grown by 20% from the previous quarter but it has contracted by 14% YoY
The equity has declined by 18% since the previous quarter but it is up by 9% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.